Partnership aims to create recombinant nanobodies to treat immune disorders

Study shows AP-325 offers lasting pain relief without central side effects

Funding led by new investors FSG and EIC Fund

Positive opinion issued for marketing authorisation extension

Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25

Patients and care partners may find once every four weeks maintenance dosing easier

Study highlights VE303’s potential in reducing recurrent CDI

Comparison shows improved survival rates for pancreatic cancer treatment

Orphan drug designation offers development incentives and potential market exclusivity

Phase 3 trial shows promising pain relief for acute pain patients